These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 22290956)

  • 21. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
    Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS
    Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Central nervous system infection due to Cryptococcus gattii sensu lato in India: Analysis of clinical features, molecular profile and antifungal susceptibility.
    Lahiri Mukhopadhyay S; Bahubali VH; Manjunath N; Swaminathan A; Maji S; Palaniappan M; Parthasarathy S; Chandrashekar N
    Mycoses; 2017 Nov; 60(11):749-757. PubMed ID: 28736880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cerebral infection caused by Cryptococcus gattii: a case report and antifungal susceptibility testing.
    Soares BM; Santos DA; Kohler LM; da Costa César G; de Carvalho IR; dos Anjos Martins M; Cisalpino PS
    Rev Iberoam Micol; 2008 Dec; 25(4):242-5. PubMed ID: 19071894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro combination between antifungals and diphenyl diselenide against Cryptococcus species.
    Rossato L; Loreto ES; Venturini TP; de Azevedo MI; Al-Hatmi AMS; Santurio JM; Alves SH
    Mycoses; 2019 Jun; 62(6):508-512. PubMed ID: 30776159
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Azole resistance in Cryptococcus gattii from the Pacific Northwest: Investigation of the role of ERG11.
    Gast CE; Basso LR; Bruzual I; Wong B
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5478-85. PubMed ID: 23979758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro susceptibility of Cryptococcus gattii clinical isolates.
    Gomez-Lopez A; Zaragoza O; Dos Anjos Martins M; Melhem MC; Rodriguez-Tudela JL; Cuenca-Estrella M
    Clin Microbiol Infect; 2008 Jul; 14(7):727-30. PubMed ID: 18558948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Punicalagin triggers ergosterol biosynthesis disruption and cell cycle arrest in Cryptococcus gattii and Candida albicans : Action mechanisms of punicalagin against yeasts.
    Silva TC; de Ávila RI; Zara ALSA; Santos AS; Ataídes F; Freitas VAQ; Costa CR; Valadares MC; Silva MDRR
    Braz J Microbiol; 2020 Dec; 51(4):1719-1727. PubMed ID: 32856241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Curcumin enhances the activity of fluconazole against Cryptococcus gattii-induced cryptococcosis infection in mice.
    da Silva DL; Magalhães TF; Dos Santos JR; de Paula TP; Modolo LV; de Fátima A; Buzanello Martins CV; Santos DA; de Resende-Stoianoff MA
    J Appl Microbiol; 2016 Jan; 120(1):41-8. PubMed ID: 26442997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro susceptibility testing of amphotericin B for Cryptococcus neoformans variety grubii AFLP1/VNI and Cryptococcus gattii AFLP6/VGII by CLSI and flow cytometry.
    Morales BP; Trilles L; Bertho ÁL; Junior IN; de Oliveira Rde V; Wanke B; Lazéra Mdos S
    Mycoses; 2015 May; 58(5):273-9. PubMed ID: 25756839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antimicrobial Octapeptin C4 Analogues Active against Cryptococcus Species.
    Chitty JL; Butler MS; Suboh A; Edwards DJ; Cooper MA; Fraser JA; Robertson AAB
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antifolates inhibit Cryptococcus biofilms and enhance susceptibility of planktonic cells to amphotericin B.
    de Aguiar Cordeiro R; Mourão CI; Rocha MF; de Farias Marques FJ; Teixeira CE; de Oliveira Miranda DF; Neto LV; Brilhante RS; de Jesus Pinheiro Gomes Bandeira T; Sidrim JJ
    Eur J Clin Microbiol Infect Dis; 2013 Apr; 32(4):557-64. PubMed ID: 23192488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determination of the minimum inhibitory concentration of Cryptococcus neoformans and Cryptococcus gattii against fluconazole by flow cytometry.
    Morales BP; Junior IN; Trilles L; Bertho AL; Oliveira Rde V; Nishikawa MM; Elias Mdos S; Wanke B; Lazéra Mdos S
    Med Mycol; 2014 Jan; 52(1):90-8. PubMed ID: 23808405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Minimum inhibitory concentrations of antifungals against invasive isolates of Cryptococcus species worldwide: Global antifungal antimicrobial testing leadership and surveillance program, 2010-2020.
    Jean SS; Liu CY; Huang YT; Ko WC; Ho MW; Liu IM; Hsieh PC; Hsueh PR
    Int J Antimicrob Agents; 2024 Mar; 63(3):107090. PubMed ID: 38242250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heteroresistance of Cryptococcus gattii to fluconazole.
    Varma A; Kwon-Chung KJ
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2303-11. PubMed ID: 20385871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
    Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
    Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates.
    Hagen F; Illnait-Zaragozi MT; Bartlett KH; Swinne D; Geertsen E; Klaassen CH; Boekhout T; Meis JF
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5139-45. PubMed ID: 20855729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.
    Espinel-Ingroff A; Aller AI; Canton E; Castañón-Olivares LR; Chowdhary A; Cordoba S; Cuenca-Estrella M; Fothergill A; Fuller J; Govender N; Hagen F; Illnait-Zaragozi MT; Johnson E; Kidd S; Lass-Flörl C; Lockhart SR; Martins MA; Meis JF; Melhem MS; Ostrosky-Zeichner L; Pelaez T; Pfaller MA; Schell WA; St-Germain G; Trilles L; Turnidge J
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5898-906. PubMed ID: 22948877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Environmental Triazole Induces Cross-Resistance to Clinical Drugs and Affects Morphophysiology and Virulence of Cryptococcus gattii and C. neoformans.
    Bastos RW; Carneiro HCS; Oliveira LVN; Rocha KM; Freitas GJC; Costa MC; Magalhães TFF; Carvalho VSD; Rocha CE; Ferreira GF; Paixão TA; Moyrand F; Janbon G; Santos DA
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109169
    [No Abstract]   [Full Text] [Related]  

  • 39. In vitro susceptibility of the yeast pathogen cryptococcus to fluconazole and other azoles varies with molecular genotype.
    Chong HS; Dagg R; Malik R; Chen S; Carter D
    J Clin Microbiol; 2010 Nov; 48(11):4115-20. PubMed ID: 20844209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India.
    Gutch RS; Nawange SR; Singh SM; Yadu R; Tiwari A; Gumasta R; Kavishwar A
    Braz J Microbiol; 2015; 46(4):1125-33. PubMed ID: 26691471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.